Iodothyronine deiodinases expression in thyroid neoplasias;Expressão das iodotironinas desiodases nas neoplasias tireoidianas

Arquivos Brasileiros de Endocrinologia e Metabologia

Volumn 51, Issue 5, 2007, Pages 690-700

  Souza Meyer, Erika L ^a   Wagner, Márcia S ^a   Maia, Ana Luiza ^a  

^a HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Gene expression; Iodothyronine deiodinases; Neoplasia

Indexed keywords

EID: 35348920084     PISSN: 00042730     EISSN: 16779487     Source Type: Journal    
DOI: 10.1590/s0004-27302007000500006     Document Type: Review

References (87)

1. Bianco AC, Salvatore D, Gereben B, Berry MJ, Larsen PR. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr Rev 2002;23:38-89.
2. Borek C, Guernsey DL, Ong A, Endelman IS. Critical role played by thyroid hormone in induction of neoplastic transformation by chemical carcinogens in tissue culture. Proc Natl Acad Sci USA 1983;80:5749-52.
3. Guernsey DL, Borek C, Edelman IS. Crucial role of thyroid hormone in X-ray-induced neoplastic transformation in cell culture. Proc Natl Acad Sci USA 1981;78:5708-11.
4. Lemaire M, Bayens W, de Saint-Georges L, Baugnet-Mahieu L. Thyroid hormone influence on the growth of hepatoma HW-165 in Wistar rats. Biomedicine 1981;34:133-9.
5. Leuthauser SWC, Guernsey DL. Thyroid hormone affects the expression of neoplastic transformation induced by DNA-transfection. Cancer Lett 1987;35:321-6.
6. Garcia-Silva S, Aranda A. The thyroid hormone receptor is a suppressor of ras-mediated transcription, proliferation and transformation. Mol Cell Biol 2004;24:7514-23.
7. Kato Y, Ying H, Willingham MC, Cheng S-Y. A tumor suppressor role for thyroid hormone β receptor in a mouse model of thyroid carcinogenesis. Endocrinology 2004;145:4430-8.
8. Lin KH, Shieh HY, Chen SL, Hsu HC. Expression of mutant thyroid hormone nuclear receptors in human hepatocellular carcinoma cells. Mol Carcinog 1999;26:53-61.
9. Kamiya Y, Puzianowska-Kuznicka M, McPhie P, Nauman J, Cheng SY, Nauman A. Expression of mutant thyroid hormone nuclear receptors is associated with renal cell carcinoma. Carcinogenesis 2002;23:25-33.
10. Puzianowska-Kuznicka M, Krystyniak A, Madej A, Cheng SY, Nauman J. Functionally impaired TR mutants are present in thyroid papillary cancer. J Clin Endocrinol Metab 2002;87:1120-8.
11. Cheng SY. Thyroid hormone receptor mutations in cancer. Mol Cel Endocrinol 2003;213:23-30.
12. Schlumberger M, Pacini F. Thyroid tumors. Paris: Éditions Nucléon, 2003.
13. Hedinger C, Williams ED, Sobin LH. Histological typing of thyroid tumours. International histological classification of tumors. World Health Organization, vol. 11, Second Edition, Springer-Verlag, Berlin, 1988.
14. Tanaka K, Otsuki T, Sonoo H, Yamamoto Y, Udagawa K, Kunisue H, et al. Semi-quantitative comparison of the differentiation markers and sodium iodide symporter messenger ribonucleic acids in papillary thyroid carcinomas using RTPCR. Eur J Endocrinol 2000;142:340-6.
15. Arturi F, Russo D, Bidart JM, Scarpelli D, Schlumberger M, Filetti S. Expression pattern of the pendrin and sodium/iodide symporter genes in human thyroid carcinoma cell lines and human thyroid tumors. Eur J Endocrinol 2001;145:129-35.
16. Gerard AC, Daumerie C, Mestdagh C, Gohy S, De Burbure C, Costagliola S, et al. Correlation between the loss of thyroglobulin iodination and the expression of thyroid-specific proteins involved in iodine metabolism in thyroid carcinomas. J Clin Endocrinol Metab 2003;88:4977-83.
17. Savin S, Cvejic D, Isic T, Petrovic I, Paunovic I, Tatic S, et al. Thyroid peroxidase immunohistochemistry in differential diagnosis of thyroid tumors. Endocr Pathol 2006;17:53-60.
18. Spitzweg C, Morris JC. The sodium iodide symporter: its pathophysiological and therapeutic implications. Clin Endocrinol 2002;57:559-74.
19. Mirebeau-Prunier D, Guyetant S, Rodien P, Franc B, Baris O, Rohmer V, et al. Decreased expression of thyrotropin receptor gene suggests a high-risk subgroup for oncocytic adenoma. Eur J Endocrinol 2004;150:269-76.
20. Khörle J, Oertel M, Hoang-Vu C, Schnieders F, Brabant G. Type I 5′-deiodinase - a marker for differentiated thyroid carcinoma? Exp Clin Endocrinol 1993;101:60-72.
21. Khörle J. Thyroid carcinoma: interrelationships between local thyroid metabolism by the type I 5′-deiodinase and the expression of thyroid hormone receptors and other thyroid specific (de)differentiation markers. Curr Top Pathol 1997;91:83-116.
22. Huang Y, Prasad M, Lemon WJ, Hampel H, Wright FA, Kornacker K, et al. Gene expression in papillary thyroid carcinoma reveals highly consistent profiles. Proc Natl Acad Sci USA 2001;98:15004-49.
23. Murakami M, Araki O, Hosoi Y, Kamiya Y, Morimura T, Ogiwara T, et al. Expression and regulation of type II iodothyronine deiodinase in human thyroid gland. Endocrinology 2001; 142:2961-7.
24. Souza Meyer EL, Dora JM, Wagner MS, Maia AL. Decreased type 1 iodothyronine deiodinase expression might be an early and discrete event in thyroid cell dedifferentiation towards papillary carcinoma. Clin Endocrinol 2005;62:672-8.
25. Arnaldi LAT, Borra RC, Maciel RMB, Cerutti JM. Gene expression profiles reveal that DCN, DIO1, and DIO2 are underexpressed in benign and malignant thyroid tumors. Thyroid 2005;15:210-21.
26. Khörle J. Guard your master: thyroid hormones receptors protect their gland of origin from thyroid cancer. Endocrinology 2004;145:4427-9.
27. Parma J, Duprez L, Van Sande J, Hermans J, Rocmans J, Van Vliet G, et al. Diversity and prevalence of somatic mutations in the thyrotropin receptor and Gsα genes as a cause of toxic thyroid adenomas. J Clin Endocrinol Metab 1997;82:2695-701.
28. Paschke R, Krohn K. Clinical review 133 - Progress in understanding the etiology of thyroid autonomy. J Clin Endocrinol Metab 2001;86:3336-45.
29. Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE, Fagin JA. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003;63:1454-7.
30. Fagin JA. Challenging dogma in thyroid cancer molecular genetic-role of RET/PTC and BRAF in tumor initiation. J Clin Endocrinol Metab 2004;89:4264-6.
31. Santoro M, Melillo M, Carlomagno F, Vecchio G, Fusco A. Minireview: RET: normal and abnormal functions. Endocrinology 2004;145:5448- 51.
32. Cheung L, Messina M, Gill A, Clarkson A, Learoyd D, Delbridge L, et al. Detection of the PAX8-PPARγ fusion oncogene in both follicular thyroid carcinomas and adenomas. J Clin Endocrinol Metab 2003;88:354-7.
33. Nikiforova MN, Lynch RA, Biddinger PW, Alexander EA, Dorn GW, Tallini G, et al. RAS point mutations and PAX8-PPARγ rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab 2003;88:2318-26.
34. Suarez HG. Genetic alterations in human epithelial tumors. Clin Endocrinol 1998;48:531-46.
35. Maciel RMB, Kimura ET, Cerutti JM. Patogênese dos tumores diferenciados da tireóide. Arq Bras Endocrinol Metab 2005;49:691-700.
36. Silva JE. Thyroid hormone control of thermogenesis and energy balance. Thyroid 1995;5:481-92.
37. St. Germain DL. Development effects of thyroid hormone: the role of deiodinases in regulatory control. Biochem Society Transactions 1999;27:83-8.
38. Wu Y, Koening RJ. Gene regulation by thyroid hormone. Trends Endocrinol Metab 2000;11:207-11.
39. St. Germain DL, Galton VA. The deiodinase family of selenoproteins. Thyroid 1997;7:655-68.
40. Kuiper GG, Kester MH, Peeters RP, Visser TJ. Biochemical mechanisms of thyroid hormone deiodination. Thyroid 2005;15:787-98.
41. Salvatore D, Tu H, Harney JW, Larsen PR. Type 2 iodothyronine deiodinase is highly expressed in human thyroid. J Clin Invest 1996;98:962-8.
42. Ishii H, Inada M, Tanaka K, Mashio Y, Naito K, Nishikawa M, et al. Triiodothyronine generation from thyroxine in human thyroid: enhanced conversion in Graves' thyroid tissue. J Clin Endocrinol Metab 1981;52:1211-7.
43. Köhrle J. Local activation and inactivation of thyroid hormones: the deiodinase family. Mol Cell Endocrinol 1999;151:103-19.
44. Maia AL, Kim BW, Huang SA, Harney JW, Larsen PR. Type 2 iodothyronine deiodinase is the major source of plasma T3 in euthyroid humans. J Clin Invest 2005;115:2524-33.
45. Visser TJ. Role of sulfation in thyroid hormone metabolism. Chem Biol Interact 1994;92:293-303.
46. 3 metabolism in normal and type 1 deiodinase-deficient mice. Endocrinology 1995;136:4842-9.
47. Jakobs TC, Schmutzler C, Meissner J, Kohrle J. The promoter of the human type I 5′-deiodinase gene-mapping of the transcription start site and identification of a DR+4 thyroid hormone-responsive element. Eur J Biochem 1997;247:88-97.
48. Zhang C, Kim S, Harney JW, Larsen PR. Further characterization of thyroid hormone response elements in the human type 1 iodothyronine deiodinase gene. Endocrinology 1998;247:288-97.
49. Ishii H, Inada M, Tanaka K, Mashio Y, Naito K, Nishikawa M, et al. Induction of outer and inner ring monodeiodinases in human thyroid gland by thyrotropin. J Clin Endocrinol Metab 1983;57:500-5.
50. Toyoda N, Nishikawa M, Mori Y, Yoshimura M, Masaki H, Gondou A, et al. Identification of a 27-kilodalton protein with the properties of type I iodothyronine 5′-deiodinase in human thyroid gland. J Clin Endocrinol Metab 1992;74:533-8.
51. Schrek R, Schnieders F, Schmutzler C, Khörle J. Retinoids stimulate type I iodothyronine 5′-deiodinase activity in human follicular thyroid carcinoma cell lines. J Clin Endocrinol Metab 1994;79:791-8.
52. Fagin JA. Molecular pathogenesis of tumors of thyroid follicular cells. In: Fagin JA (ed). Thyroid cancer. Boston: Kluwer Academic Publishers, 1998. pp. 59-83.
53. Pachucki J, Ambroziak M, Tanski J, Luczak J, Nauman J, Nauman A. Type I 5′-iodothyronine deiodinase activity and mRNA are remarkably reduced in renal clear cell carcinoma. J Endocrinol Invest 2001;24:253-61.
54. Sabatino L, Iervasi G, Ferrazzi P, Francesconi D, Chopra IJ. A study of iodothyronine 5′-monodeiodinase activities in normal and pathological tissues in man and their comparison with activities in rat tissues. Life Sci 2000;68:191-202.
55. Wawrzynska L, Sakowicz A, Rudzinski P, Langfort R, Kurzyna M. The conversion of thyroxine to triiodothyronine in the lung: comparison of activity of type I iodothyronine 5′ deiodinase in lung cancer with peripheral lung tissues. Monaldi Arch Chest Dis 2003;59:140-5.
56. Dutkiewicz S, Witeska A, Nauman A. the deiodination of thyroxine to triiodothyronine in the testes of patients with prostate cancer. Int Urol Nephrol 1995;27:81-5.
57. Macejova D, Liska J, Brtko J. Mammary gland carcinoma-related increase of type I iodothyronine 5′-deiodinase activity in Sprague-Dawley rats. Gen Physiol Biophys 2001;20:293-302.
58. th Annual Meeting, San Francisco, CA, 2002, p. 299 (Abstract).
59. Aceves C, Rojas-Huidobro R. Effect of suckling and adrenergic stimulation on peripheral deiodination in lactating rats: differential expression of type 1 deiodinases mRNA forms. J Endocrinol 2001;171:533-40.
60. García-Solís P, Aceves C. 5′deiodinase in two breast cancer cell lines: effect of triiodothyronine, isoproterenol and retinoids. Mol Cell Endocrinol 2003;201:25-31.
61. Campos-Barros A, Hoell T, Musa A, Sampaolo S, Stoltenburg G, Pinna G, et al. Phenolic and tyrosil ring iodothyronine deiodination and thyroid hormone concentrations in the human central nervous system. J Clin Endocrinol Metab 1996;81:2179-85.
62. Tannahill LA, Visser TJ, McCabe CJ, Kachilele S, Boelaert K, Sheppard Mc, et al. Dysregulation of iodothyronine deiodinase enzyme expression and function in human pituitary tumours. Clin Endocrinol 2002;56:735-43.
63. Baur A, Buchfelder M, Kohrle J. Expression of 5′-deiodinase enzymes in normal pituitaries and in various human pituitary adenomas. Eur J Endocrinol 2002;147:263-8.
64. Silva JE, Larsen PR. Comparison of iodothyronine 5′-deiodinase and other thyroid-hormone-dependent enzyme activities in the cerebral cortex of hypothyroid neonatal rat. Evidence for adaptation to hypothyroidism. J Clin Invest 1982;70:1110-23.
65. Burmeister LA, Pachucki J, St. Germain DL. Thyroid hormones inhibit type 2 iodothyronine deiodinase in the rat cerebral cortex by both pre-and posttranslational mechanisms. Endocrinology 1997;138:5231-7.
66. Gereben B, Salvatore D. Pretranslational regulation of type 2 deiodinase. Thyroid 2005;15:855-64.
67. Kim BW, Daniels GH, Harrison BJ, Price A, Harney JW, Larsen PR, et al. Overexpression of type 2 iodothyronine deiodinase in follicular carcinoma as cause of low circulating free thyroxine levels. J Clin Endocrinol Metab 2003;88:594-8.
68. Takano T, Miyauchi A, Ito Y, Amino N. Thyroxine to triiodothyronine hyperconversion thyrotoxicosis in patients with large metastases of follicular thyroid carcinoma. Thyroid 2006;16:615-8.
69. Magrassi L, Butti G, Silini E, Bono F, Paoletti P, Milanesi G. The expression of genes of the steroid-thyroid hormone receptor superfamily in central nervous system tumors. Anticancer Res 1993;13:859-66.
70. Toms SA, Hercbergs A, Liu J, Kondo S, Barnett GH, Casey G, et al. Thyroid hormone depletion inhibits astrocytoma proliferation via a p53-independent induction of p21 (WAF/1CIP1). Anticancer Res 1998;18:289-94.
71. Murakami M, Araki O, Morimura T, Hosoi Y, Mizuma H, Yamada M, et al. Expression of type II iodothyronine deiodinase in brain tumors. J Clin Endocrinol Metab 2000;85:4403-6.
72. Nauman P, Bonicki W, Michalik R, Warzecha A, Czernicki Z. The concentration of thyroid hormones and activities of iodothyronine deiodinases are altered in human brain gliomas. Folia Neuropathol 2004;42:67-73.
73. Mori K, Yoshida K, Kayama T, Kaise N, Fukazama H, Kiso Y, et al. Thyroxine 5-deiodinase in human brain tumors. J Clin Endocrinol Metab 1993;77:1198-202.
74. Barrera-Hernandez G, Park KS, Dace A, Zhan Q, Cheng SY. Thyroid hormone-induced cell proliferation in GC cells is mediated by changes in G1 cyclin/cyclin-dependent kinase levels and activity. Endocrinology 1999;140:5267-74.
75. Stahl JH, Kendall SK, Brinkmeier ML, Greco TL, Watkins-Chow DE, Campos-Barros A, et al. Thyroid hormone is essential for pituitary somatotropes and lactotropes. Endocrinology 1999;140:1884-92.
76. Canettieri G, Franchi A, Sibilla R, Guzman E, Centanni M. Functional characterization of the CRE/TATA box unit of type 2 deiodinase gene promoter in a human choriocarcinoma cell line. J Mol Endocrinol 2004;33:51-8.
77. Rihn B, Mohr S, McDowell SA, Binet S, Loubinox J, Galateau F, et al. Differential gene expression in mesothelioma. FEBS Lett 2000;480:95-100.
78. Curcio C, Baqui MM, Salvatore D, Rihn BH, Mohr S, Harney JW, et al. The human type 2 iodothyronine deiodinase is a selenoprotein highly expressed in a mesothelioma cell line. J Biol Biochem 2001;276:30183-7.
79. Morimura T, Tsunekawa K, Kasahara T, Seki K, Ogiwara T, Mori M, et al. Expression of type 2 iodothyronine deiodinase in human osteoblast is stimulated by thyrotropin. Endocrinology 2005;146:2077-84.
80. Huang SA, Dorfman DM, Genest DR, Salvatore D, Larsen PR. Type 3 iodothyronine deiodinase is highly expressed in the human uteroplacental unit and in fetal epithelium. J Clin Endocrinol 2003;88:1384-8.
81. Bates JM, St. Germain DL, Galton VA. Expression profiles of the three iodothyronine deiodinases, D1, D2, and D3, in developing rat. Endocrinology 1999;140:844-51.
82. Slominski A, Wortsman J, Khon L, Ain KB, Venkataraman GM, Pisarchik A, et al. Expression of hypothalamic-pituitary-thyroid axis related genes in the human skin. J Invest Dermatol 2002;119:1449-55.
83. Kester MHA, Kuiper GGJM, Versteeg R, Visser T. Regulation of type III iodothyronine deiodinase expression in human cell lines. Endocrinology 2006;147:5845-54.
84. Baur A, Khorle J. Type 1 deiodinase is stimulated by iodothyronines and involved in thyroid hormone metabolism in human somatomammotroph GX cells. Eur J Endocrinol 1999;140:367-70.
85. Huang SA, Tu HM, Harney JW, Venihaki M, Butte AJ, Kozakewich HPW, et al. Severe hypothyroidism caused by type 3 iodothyronine deiodinase in infantile hemangiomas. N Eng J Med 2000;343:185-9.
86. Huang SA, Fish SA, Dorfman DM, Salvatore D, Kozakewich HP, Mandel SJ, et al. A 21-year-old Woman with consumptive hypothyroidism due to a vascular tumor expressing type 3 iodothyronine deiodinase. J Clin Endocrinol Metab 2002;87:4457-46.
87. Huang A. Physiology and pathophysiology of type 3 deiodinase in humans. Thyroid 2005;15:875-81.